Real-time US stock institutional ownership tracking and fund flow analysis to understand who owns and is buying the stock. We monitor 13F filings and institutional buying patterns because large investors often have superior information.
Dermata Therapeutics Inc. (DRMA), a clinical-stage biotherapeutics firm focused on dermatological treatments, is trading at $1.34 as of 2026-04-20, marking a 1.47% decline from the prior trading session’s close. No recent earnings data is available for the firm as of this analysis, so recent price action has been driven primarily by technical factors, broader biotech sector sentiment, and investor positioning around expected future operational updates. This analysis outlines key market context,
Dermata (DRMA) Stock Hot Topic (Institutional Selling) 2026-04-20 - Index Investing
DRMA - Stock Analysis
3973 Comments
1745 Likes
1
Libera
Consistent User
2 hours ago
Who else is curious but unsure?
👍 215
Reply
2
Siella
Active Contributor
5 hours ago
This feels like I should go back.
👍 73
Reply
3
Anquenette
Elite Member
1 day ago
This is the kind of thing you only see too late.
👍 191
Reply
4
Youki
Consistent User
1 day ago
This feels illegal but I can’t explain why.
👍 214
Reply
5
Navier
Experienced Member
2 days ago
I need sunglasses for all this brilliance. 🕶️
👍 233
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.